There are 2949 resources available
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Presenter: Byoung Chul Cho
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Presenter: Li Zhang
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1021O - Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
Presenter: Michael Millward
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1156O - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Presenter: Jianming Xu
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
CN20 - Oral targeted therapy dose adaptation in geriatric cancer patients: A real life French cohort
Presenter: Fanny Leenhardt
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Abstract
Slides
Webcast
Why do we need phase I clinical trials?
Presenter: Martijn Lolkema
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
From referral for to participation in phase I clinical trials: Patient journeys and preliminary results in the development of an online value clarification tool
Presenter: Liza Van Lent
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Slides
Webcast
Q&A live discussion
Presenter: Ruben Martin Payo
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Webcast